402 related articles for article (PubMed ID: 35683015)
1. Molecular Mechanism of Pathogenesis and Treatment Strategies for AL Amyloidosis.
Ikura H; Endo J; Kitakata H; Moriyama H; Sano M; Fukuda K
Int J Mol Sci; 2022 Jun; 23(11):. PubMed ID: 35683015
[TBL] [Abstract][Full Text] [Related]
2. The Ultrastructure of Tissue Damage by Amyloid Fibrils.
Koike H; Katsuno M
Molecules; 2021 Jul; 26(15):. PubMed ID: 34361762
[TBL] [Abstract][Full Text] [Related]
3. Amino acid sequence homology of monoclonal serum free light chain dimers and tissue deposited light chains in AL amyloidosis: a pilot study.
Goldis R; Kaplan B; Arad M; Dispenzieri A; Dasari S; Kukuy OL; Simon AJ; Dori A; Shavit-Stein E; Ziv T; Murray D; Kourelis T; Gertz MA; Dominissini D; Magen H; Muchtar E
Clin Chem Lab Med; 2024 Feb; 62(3):464-471. PubMed ID: 37747270
[TBL] [Abstract][Full Text] [Related]
4. Differential recruitment efficacy of patient-derived amyloidogenic and myeloma light chain proteins by synthetic fibrils-A metric for predicting amyloid propensity.
Martin EB; Williams A; Wooliver C; Heidel RE; Adams S; Dunlap J; Ramirez-Alvarado M; Blancas-Mejia LM; Lands RH; Kennel SJ; Wall JS
PLoS One; 2017; 12(3):e0174152. PubMed ID: 28350808
[TBL] [Abstract][Full Text] [Related]
5. Immunoglobulin light chain amyloid aggregation.
Blancas-Mejia LM; Misra P; Dick CJ; Cooper SA; Redhage KR; Bergman MR; Jordan TL; Maar K; Ramirez-Alvarado M
Chem Commun (Camb); 2018 Sep; 54(76):10664-10674. PubMed ID: 30087961
[TBL] [Abstract][Full Text] [Related]
6. Fatal amyloid formation in a patient's antibody light chain is caused by a single point mutation.
Kazman P; Vielberg MT; Pulido Cendales MD; Hunziger L; Weber B; Hegenbart U; Zacharias M; Köhler R; Schönland S; Groll M; Buchner J
Elife; 2020 Mar; 9():. PubMed ID: 32151314
[TBL] [Abstract][Full Text] [Related]
7. A constant domain mutation in a patient-derived antibody light chain reveals principles of AL amyloidosis.
Rottenaicher GJ; Absmeier RM; Meier L; Zacharias M; Buchner J
Commun Biol; 2023 Feb; 6(1):209. PubMed ID: 36823438
[TBL] [Abstract][Full Text] [Related]
8. In vitro co-expression of human amyloidogenic immunoglobulin light and heavy chain proteins: a relevant cell-based model of AL amyloidosis.
Klimtchuk ES; Prokaeva TB; Spencer BH; Gursky O; Connors LH
Amyloid; 2017 Jun; 24(2):115-122. PubMed ID: 28632419
[TBL] [Abstract][Full Text] [Related]
9. Dissecting the Molecular Features of Systemic Light Chain (AL) Amyloidosis: Contributions from Proteomics.
Rognoni P; Mazzini G; Caminito S; Palladini G; Lavatelli F
Medicina (Kaunas); 2021 Aug; 57(9):. PubMed ID: 34577839
[TBL] [Abstract][Full Text] [Related]
10. Amyloidogenic light chains impair plasma cell survival.
Pick M; Lebel E; Elgavish S; Benyamini H; Nevo Y; Hertz R; Bar-Tana J; Rognoni P; Merlini G; Gatt ME
Haematologica; 2023 Dec; 108(12):3359-3371. PubMed ID: 37381778
[TBL] [Abstract][Full Text] [Related]
11. Thermal stability threshold for amyloid formation in light chain amyloidosis.
Poshusta TL; Katoh N; Gertz MA; Dispenzieri A; Ramirez-Alvarado M
Int J Mol Sci; 2013 Nov; 14(11):22604-17. PubMed ID: 24248061
[TBL] [Abstract][Full Text] [Related]
12. Light chain amyloidosis - current findings and future prospects.
Baden EM; Sikkink LA; Ramirez-Alvarado M
Curr Protein Pept Sci; 2009 Oct; 10(5):500-508. PubMed ID: 19538145
[TBL] [Abstract][Full Text] [Related]
13. Review: immunoglobulin light chain amyloidosis--the archetype of structural and pathogenic variability.
Bellotti V; Mangione P; Merlini G
J Struct Biol; 2000 Jun; 130(2-3):280-9. PubMed ID: 10940232
[TBL] [Abstract][Full Text] [Related]
14. Systemic Amyloidosis Due to Clonal Plasma Cell Diseases.
Bianchi G; Kumar S
Hematol Oncol Clin North Am; 2020 Dec; 34(6):1009-1026. PubMed ID: 33099420
[TBL] [Abstract][Full Text] [Related]
15. Identification of two principal amyloid-driving segments in variable domains of Ig light chains in systemic light-chain amyloidosis.
Brumshtein B; Esswein SR; Sawaya MR; Rosenberg G; Ly AT; Landau M; Eisenberg DS
J Biol Chem; 2018 Dec; 293(51):19659-19671. PubMed ID: 30355736
[TBL] [Abstract][Full Text] [Related]
16. AL amyloidosis with non-amyloid forming monoclonal immunoglobulin deposition; a case mimicking AHL amyloidosis.
Manabe S; Iwasaki C; Hatano M; Kametani F; Yazaki M; Nitta K; Nagata M
BMC Nephrol; 2018 Nov; 19(1):337. PubMed ID: 30466387
[TBL] [Abstract][Full Text] [Related]
17. Protease-sensitive regions in amyloid light chains: what a common pattern of fragmentation across organs suggests about aggregation.
Mazzini G; Ricagno S; Caminito S; Rognoni P; Milani P; Nuvolone M; Basset M; Foli A; Russo R; Merlini G; Palladini G; Lavatelli F
FEBS J; 2022 Jan; 289(2):494-506. PubMed ID: 34482629
[TBL] [Abstract][Full Text] [Related]
18. Mutations in specific structural regions of immunoglobulin light chains are associated with free light chain levels in patients with AL amyloidosis.
Poshusta TL; Sikkink LA; Leung N; Clark RJ; Dispenzieri A; Ramirez-Alvarado M
PLoS One; 2009; 4(4):e5169. PubMed ID: 19365555
[TBL] [Abstract][Full Text] [Related]
19. 2A4 binds soluble and insoluble light chain aggregates from AL amyloidosis patients and promotes clearance of amyloid deposits by phagocytosis
Renz M; Torres R; Dolan PJ; Tam SJ; Tapia JR; Li L; Salmans JR; Barbour RM; Shughrue PJ; Nijjar T; Schenk D; Kinney GG; Zago W
Amyloid; 2016 Sep; 23(3):168-177. PubMed ID: 27494229
[TBL] [Abstract][Full Text] [Related]
20. Current status and prospect of anti-amyloid fibril therapy in AL amyloidosis.
Wang J; Li J; Zhong L
Blood Rev; 2024 Jul; 66():101207. PubMed ID: 38692939
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
